Patent 9290760 was granted and assigned to Alnylam Pharmaceuticals on March, 2016 by the United States Patent and Trademark Office.
The present invention provides effective motifs for RNA agents conjugated to at least one ligand, which are advantageous for the in vivo delivery of iRNA duplex agents. Additionally, the present invention provides methods of making these compositions, as well as methods of introducing these iRNA duplex agents into cells using these compositions, e.g., for the treatment of various disease conditions.